Is Kura Oncology Stock a Good Investment?
Kura Oncology Investment Advice | KURA |
- Examine Kura Oncology's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Kura Oncology's leadership team and their track record. Good management can help Kura Oncology navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Kura Oncology's business and its evolving consumer preferences.
- Compare Kura Oncology's performance and market position to its competitors. Analyze how Kura Oncology is positioned in terms of product offerings, innovation, and market share.
- Check if Kura Oncology pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Kura Oncology's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Kura Oncology stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Kura Oncology is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Somewhat reliable | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Slowly supersedes the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Kura Oncology Stock
Researching Kura Oncology's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 99.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.47. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Kura Oncology recorded a loss per share of 2.35. The entity had not issued any dividends in recent years.
To determine if Kura Oncology is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Kura Oncology's research are outlined below:
| Kura Oncology generated a negative expected return over the last 90 days | |
| Kura Oncology has high historical volatility and very poor performance | |
| Net Loss for the year was (152.63 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Kura Oncology currently holds about 450.26 M in cash with (124.82 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.73. | |
| Kura Oncology has a frail financial position based on the latest SEC disclosures | |
| Over 99.0% of the company shares are owned by institutional investors | |
| Latest headline from news.google.com: Kura Oncologys chief legal officer sells 57,315 in stock - MSN |
Kura Oncology Quarterly Cash And Short Term Investments |
|
Kura Oncology uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Kura Oncology. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Kura Oncology's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 22nd of February 2024 Upcoming Quarterly Report | View | |
| 8th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 22nd of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Kura Oncology's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Kura Oncology's investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2017-05-15 | 2017-03-31 | -0.44 | -0.39 | 0.05 | 11 | ||
2016-03-17 | 2015-12-31 | -0.48 | -0.42 | 0.06 | 12 | ||
2019-05-07 | 2019-03-31 | -0.44 | -0.37 | 0.07 | 15 | ||
2023-02-23 | 2022-12-31 | -0.57 | -0.49 | 0.08 | 14 | ||
2018-05-08 | 2018-03-31 | -0.35 | -0.46 | -0.11 | 31 | ||
2015-11-13 | 2015-09-30 | -0.42 | -0.57 | -0.15 | 35 |
Kura Oncology Target Price Consensus
Kura target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Kura Oncology's target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 16 | Strong Buy |
Most Kura analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Kura stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Kura Oncology, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationKura Oncology Target Price Projection
Kura Oncology's current and average target prices are 8.03 and 28.36, respectively. The current price of Kura Oncology is the price at which Kura Oncology is currently trading. On the other hand, Kura Oncology's target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Kura Oncology Market Quote on 31st of January 2025
Target Price
Analyst Consensus On Kura Oncology Target Price
Kura Oncology Analyst Ratings
Kura Oncology's analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about Kura Oncology stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of Kura Oncology's financials, market performance, and future outlook by experienced professionals. Kura Oncology's historical ratings below, therefore, can serve as a valuable tool for investors.Know Kura Oncology's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Kura Oncology is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Kura Oncology backward and forwards among themselves. Kura Oncology's institutional investor refers to the entity that pools money to purchase Kura Oncology's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Deep Track Capital, Lp | 2024-09-30 | 2 M | Foresite Capital Management Iv, Llc | 2024-09-30 | 1.8 M | Commodore Capital Lp | 2024-09-30 | 1.8 M | Geode Capital Management, Llc | 2024-09-30 | 1.8 M | Franklin Resources Inc | 2024-09-30 | 1.6 M | Tcg Crossover Management, Llc | 2024-09-30 | 1.4 M | Siren, L.l.c. | 2024-09-30 | 1.3 M | Morgan Stanley - Brokerage Accounts | 2024-09-30 | 1.2 M | Citadel Advisors Llc | 2024-09-30 | 1.2 M | Suvretta Capital Management, Llc | 2024-09-30 | 7.7 M | Blackrock Inc | 2024-09-30 | 7.2 M |
Kura Oncology's market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 624.44 M.Market Cap |
|
Kura Oncology's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.31) | (0.32) | |
| Return On Capital Employed | (0.46) | (0.44) | |
| Return On Assets | (0.31) | (0.32) | |
| Return On Equity | (0.35) | (0.36) |
Determining Kura Oncology's profitability involves analyzing its financial statements and using various financial metrics to determine if Kura Oncology is a good buy. For example, gross profit margin measures Kura Oncology's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Kura Oncology's profitability and make more informed investment decisions.
Please note, the presentation of Kura Oncology's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Kura Oncology's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Kura Oncology's management manipulating its earnings.
Evaluate Kura Oncology's management efficiency
Kura Oncology has return on total asset (ROA) of (0.2854) % which means that it has lost $0.2854 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4628) %, meaning that it created substantial loss on money invested by shareholders. Kura Oncology's management efficiency ratios could be used to measure how well Kura Oncology manages its routine affairs as well as how well it operates its assets and liabilities. As of January 31, 2025, Return On Tangible Assets is expected to decline to -0.32. The current year's Return On Capital Employed is expected to grow to -0.44. At present, Kura Oncology's Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 522.2 M, whereas Return On Tangible Assets are forecasted to decline to (0.32).| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 4.88 | 5.13 | |
| Tangible Book Value Per Share | 4.88 | 5.13 | |
| Enterprise Value Over EBITDA | (5.64) | (5.92) | |
| Price Book Value Ratio | 2.39 | 2.50 | |
| Enterprise Value Multiple | (5.64) | (5.92) | |
| Price Fair Value | 2.39 | 2.50 | |
| Enterprise Value | 714.2 M | 720.5 M |
The strategic initiatives led by Kura Oncology's management are central to its market success. By analyzing these initiatives, we provide a clear picture of the stock's growth prospects.
Beta 0.857 |
Basic technical analysis of Kura Stock
As of the 31st of January, Kura Oncology secures the Standard Deviation of 5.32, mean deviation of 2.62, and Risk Adjusted Performance of (0.15). Kura Oncology technical analysis lets you operate historical price patterns with an objective to determine a pattern that forecasts the direction of the firm's future prices.Kura Oncology's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Kura Oncology insiders, such as employees or executives, is commonly permitted as long as it does not rely on Kura Oncology's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Kura Oncology insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Kura Oncology's Outstanding Corporate Bonds
Kura Oncology issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Kura Oncology uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Kura bonds can be classified according to their maturity, which is the date when Kura Oncology has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Volcan Compania Minera Corp BondUSP98047AC08 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| International Game Technology Corp BondUS460599AD57 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View |
Understand Kura Oncology's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Kura Oncology's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.15) | |||
| Market Risk Adjusted Performance | (2.57) | |||
| Mean Deviation | 2.62 | |||
| Coefficient Of Variation | (519.05) | |||
| Standard Deviation | 5.32 | |||
| Variance | 28.29 | |||
| Information Ratio | (0.21) | |||
| Jensen Alpha | (1.07) | |||
| Total Risk Alpha | (1.61) | |||
| Treynor Ratio | (2.58) | |||
| Maximum Drawdown | 42.52 | |||
| Value At Risk | (5.91) | |||
| Potential Upside | 5.51 | |||
| Skewness | (4.65) | |||
| Kurtosis | 31.67 |
| Risk Adjusted Performance | (0.15) | |||
| Market Risk Adjusted Performance | (2.57) | |||
| Mean Deviation | 2.62 | |||
| Coefficient Of Variation | (519.05) | |||
| Standard Deviation | 5.32 | |||
| Variance | 28.29 | |||
| Information Ratio | (0.21) | |||
| Jensen Alpha | (1.07) | |||
| Total Risk Alpha | (1.61) | |||
| Treynor Ratio | (2.58) | |||
| Maximum Drawdown | 42.52 | |||
| Value At Risk | (5.91) | |||
| Potential Upside | 5.51 | |||
| Skewness | (4.65) | |||
| Kurtosis | 31.67 |
Consider Kura Oncology's intraday indicators
Kura Oncology intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Kura Oncology stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 67517.9 | |||
| Daily Balance Of Power | 0.68 | |||
| Rate Of Daily Change | 1.04 | |||
| Day Median Price | 7.96 | |||
| Day Typical Price | 7.98 | |||
| Price Action Indicator | 0.24 | |||
| Period Momentum Indicator | 0.34 |
Kura Oncology Corporate Filings
F4 | 28th of January 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 14th of January 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 8th of January 2025 Other Reports | ViewVerify | |
F3 | 7th of January 2025 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
Kura Stock media impact
Far too much social signal, news, headlines, and media speculation about Kura Oncology that are available to investors today. That information is available publicly through Kura media outlets and privately through word of mouth or via Kura internal channels. However, regardless of the origin, that massive amount of Kura data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Kura Oncology news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Kura Oncology relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Kura Oncology's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Kura Oncology alpha.
Kura Oncology Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Kura Oncology can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Kura Oncology Historical Investor Sentiment
Investor biases related to Kura Oncology's public news can be used to forecast risks associated with an investment in Kura. The trend in average sentiment can be used to explain how an investor holding Kura can time the market purely based on public headlines and social activities around Kura Oncology. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Kura Oncology's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Kura Oncology and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Kura Oncology news discussions. The higher the estimate score, the more favorable the investor's outlook on Kura Oncology.
Kura Oncology Corporate Management
| Kathleen Ford | Chief Officer | Profile | |
| Mollie MD | Executive Development | Profile | |
| Francis Burrows | Senior Research | Profile | |
| Roger Bakale | Clinical CMC | Profile | |
| JD Esq | Chief Secretary | Profile | |
| Marc MD | Advisor | Profile | |
| Stephen MD | Chief Officer | Profile |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kura Oncology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Kura Stock refer to our How to Trade Kura Stock guide.You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kura Oncology. If investors know Kura will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kura Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Kura Oncology is measured differently than its book value, which is the value of Kura that is recorded on the company's balance sheet. Investors also form their own opinion of Kura Oncology's value that differs from its market value or its book value, called intrinsic value, which is Kura Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kura Oncology's market value can be influenced by many factors that don't directly affect Kura Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Kura Oncology's value and its price, as these two are different measures arrived at by various means. Investors typically determine if Kura Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kura Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.